CLINAM
European Foundation for Clinical Nanomedicine
Switzerland

14/2023

14th European and Global Summit for Clinical Nanomedicine
Summit and Exhibition

Summit with sessions of three other conference organizers of excellence

Phospholipid Research Center

LIPOSOME RESEARCH DAYS
International meetings on liposomes, lipidic nanoparticles and membrane biophysics

APV MAKING SCIENCE WORK

Clinical Nanomedicine 2023: Fulfilling the Global Potential

Crossing the Horizon towards Novel Possibilities, Existing and Evolving Products, Technologies, Research and Strategies for Global Health

Preliminary Programme and Call for Papers

Basel, Switzerland from October 8. - 11. 2023

Venue: Novartis Campus Basel, Switzerland

Supporters of the CLINAM Goals and Strategy

Contents **Monday** **Tuesday** **Wednesday**

Scientific Committee or the Summit 2023

- **Prof. Dr. med. Patrick Hunziker,** Deputy Head of the Intensive Care Clinic of the University Hospital Basel (CH)
- **Prof. Dr. Lajos Balogh,** Editor-in-Chief, Precision Nanomedicine PRNANO), Boston (USA)
- **Prof. Dr. Yechezkel Barenholz,** Professor Emeritus, Head of Membrane and Liposome Research Lab, Hebrew University Hadassah Medical School, Jerusalem (IL)
- **Prof. Dr. Dr. Twan Lammers,** Institute for Experimental Molecular Imaging, RWTH, Aachen (DE)
- **Prof. Dr. med. Dong Soo Lee, Ph.D**. Chairman, Department of Nuclear Medicine Seoul National University, Seoul (KOR)
- **Dr. med. h.c. Beat Löffler, MA,** CEO, CLINAM Foundation, Basel (CH)
- **Prof. Dr. Gert Storm,** Institute for Pharmaceutical Sciences, Utrecht University, Utrecht (NL)
- **Prof. Dr. Dr. h.c. Viola Vogel,** Head of the Laboratory of Applied Mechanobiology, Department for Health Sciences and Technology (HEST), ETH, Zürich (CH)
- **PD Dr. Peter van Hoogevest**, Member of the Scientific Advisory Council, Phospholipid Research Center, Heidelberg (DE)
- **Prof. Dr. med. Christoph Alexiou**, University Hospital Erlangen (DE)
- **Prof. Dr. med. Raymond Schiffelers**, Professor of Nanomedicine; Division LAB CDL Research; UMC Utrecht; Chairman of the ETP Nanomedicine Executive Board, Utrecht (NL)
- **PD Dr. habil. Simon Drescher,** Managing Director, Phospholipid Research Center, Heidelberg (DE)
- **Prof. Dr. Theresa Allen,** University of Alberta, University of British Columbia an Organizer of the Lipid Research Days 2022, Vancouver (CAN)
- **Prof. Dr. Pieter Cullis.** Professor of Biochemistry, University of B.C. (UBC) Vancouver, Cofounder of Acuitas Therapeutics, lipid nanoparticle technology, Vancouver (CAN)
- **Dr. Martin Bornhöft,** Head of the International Association for Pharmaceutical Technology (APV), Mainz (DE)

Introduction

The nonprofit European Foundation for Clinical Nanomedicine will have after two virtual summits in 2020 & 2022 its 14th Summit as a hybrid event with personal attendance and live stream. CLINAM 14 /2023 will be the unique traditional platform with a scientific programme that will elucidate the state of the art of nanomedicine in production, development and the clinic for prevention, diagnosis and therapy. Since the development of mRNA vaccines based on lipid nanoparticles, nanomedicine has received huge awareness and has matured to a boosting field with highest recognition. This is the right moment to review the development of the technology as well as looking at the products and their use in clinical medicine at patient's bed. The achievement of the revolutionary protective wall against COVID -19 by mRNA vaccines predicts a profound acceleration of innovative drug development to the benefit of patients. However, not for all humankind: How can we enable and improve health care in countries where therapy until today is unaffordable or absent? For this, delivery of drugs by different nanoparticles shall be an important issue. All stakeholders in the field, including many high-ranking scientists, Nobel Laureates and leading managers and regulatory authorities from all continents exploit the CLINAM-summit since 15 years for new projects and making bonds for cooperation. All speakers contribute to an excellent scientific outlook. For 2023, CLINAM addressed three outstanding organizers of renowned conferences and invited them to participate with a session within the CLINAM-Summit. The different skills of the parties will give a unique interdisciplinary perspective on nanomedicine and related fields in Europe and on the International level. The international Regulatory Authorities shall have their IPRP Meeting during the Summit.

Format of the Meeting

The Summit will take place on the Novartis Campus in Basel, which is since last year open to the public. The summit shall have on one day only plenary sessions and will take place in the auditorium, which is located in the impressive building designed by the architect Frank Gehry. The exhibition, poster presentations and lunches will be in the Foyer of the halls. The CLINAM Team will organize the meeting with as few as possible hurdles for the participants and is grateful for the support that Novartis gives by making the halls available to CLINAM.

Target Audience

The faculty includes pioneers and opinion leaders in medicine, nanoscience, and targeted medicine, physicians and scientists with a background in pharmacology, biology, physics, chemistry, biophysics, medicine, materials science, and engineering. Industry members find contacts for cooperation, get insight into the novel concepts

and meet keen investigating startups, interested in working together. Developers from the pharmaceutical industry present their recent findings and research. The meeting is a particularly useful source of knowledge for the targeted medicine and delivery community. The conference is also of interest to members of the regulatory authorities as well as policymakers, all experts from industry in the field of life sciences, developers of new tools and materials for nanomedicine, and all those investigating the potential of emerging technologies in the field of healthcare and their combinations. Experts from venture companies can acquire knowledge on existing and upcoming developments and novel products in the establishing field of nanomedicine and knowledge-based medicine. Government authorities can profit from the international regulator's sessions. CLINAM is the worldwide melting pot for experts and a high-level communication platform where you meet those striving for nanomedical goals.

Preliminary Programme **(Status February 10, 2023)**

Monday, October 9, 2023 - Plenary Session and 2 separate Events

Hall 1
Monday, 08.30 – 08.45
1. Opening

08.30 **Welcome on behalf of the CLINAM-Foundation**
Dr. med. h.c. Beat Löffler, MA, CEO, European Foundation for Clinical Nanomedicine, Basel (CH)

Hall 1
Monday, 08.45 – 09.10
2. Scientific Introduction of the Summit 2023

08.45 **Worldwide Interventions for Improving Nanomedicine**
Prof. Dr. med. Patrick Hunziker, President of the International Society for Nanomedicine; CSO of the CLINAM-Foundation, Deputy Head of the Intensive Care Clinic of the University Hospital Basel (CH)

Hall 1
Monday, 09.15 - 10.00 (keynote lecture)
3. The Origin of Life

Chair NN

Title to come
NN

9.50 **Questions and Debate**

10.00 **Break**

Hall 1
Monday, 10.30 - 12.30
4. Cancer Nanomedicine

Chair **Prof. Dr. Gert Storm,** Institute for Pharmaceutical Sciences, Utrecht University, Utrecht (NL)

About Cancer nanomedicine is the best way to overcome the shortcomings of conventional cancer diagnostics and therapies.

10.30 **The Triple Effect of the Neoadjuvant Immunotherapy Revolution: More Cures, Shorter Treatments, Less Surgery**
Alexander M.M. Eggermont, MD, PhD Chief Scientific Officer, Board of Directors Professor Clinical & Translational Immunotherapy, UMCU, Utrecht University (NL), Board Comprehensive Cancer Center München (DE)

10.45 **The Role of PET and Radionuclide Therapy in Cancer Immunotherapy**
Prof. Dr. med. Andreas Kjaer, PhD, DMSc, Professor, chief physician , Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, University of Copenhagen (DK)

11.00 **Nanomedicine for Cancer and Chronic Pain**
Prof. Dr. Nathalie Pinkerton, the Pinkerton Research Group, NYU Tandon School of Engineering, Brooklyn, NY /USA)

11.15 **3D-bioprinted Cancer Models for Personalized Therapy of Nanomedicines**
Prof. Ronit Satchi-Fainaro, Professor of Pharmacology - Tel Aviv University; Head - Cancer Research and Nanomedicine Lab; Director - Cancer Biology Research Center; Director at BoD Teva Pharmaceutical industries; Member at 8400 - The Health Network, Tel Aviv University (IL)

1130 **Precision Arterial Doxorubicin Drug Delivery and Treating Soft Tissue Tumors: Long-term Follow-up**
Dr. med. Eldad Elnekave, Director Interventional Oncology Clinic, Davidoff Cancer Institute & Radiology Department, Rabin Medical Center, Chief Medical Officer, Zebra Medical Vision, LTD, Tel Aviv (IL)

11.45 **Drug Co-encapsulation in Lipid Nanoparticles for a Multimodality Approach to Cancer Therapy**
Alberto A. Gabizon, M.D., Ph.D., Director, Center of Nano-oncology, Shaare Zedek Medical Ctr. Professor of Oncology, Hebrew University-School of Medicine, Jerusalem (IL)

12.00 **Establishing a Patient-derived Glioblastoma Organoids Model that Mimics Tumor Heterogeneity in Patients**
Dr. Peter Wick, Head of the Laboratory for Particles-Biology Interactions, Empa, St. Gallen (CH)

12.15 **Questions and Debate**

12.30 **Lunch**

Hall 1
Monday, 13.00-14.30
5. Non-Biological Complex Drugs (NBCDs)
Chair **Dr. Jon de Vlieger,** Secretary of the Non-Biological Complex Drug Working Group, Lygature, Utrecht (NL)

About

Session under Construction

Hall 1
14.30 - 15.15
6. Graphene in Nanomedicine
Chair **Dr. Peter Wick,** Head of the Laboratory for Particles-Biology Interactions, EMPA, St. Gallen (CH)

About Carbon nanomaterials offer a rich toolbox of opportunities for translation in various application areas. A perspective of the unique properties and their combination that carbon nanomaterials offer for application in medicine.

14.30 **Probing Immunological Interactions of Two-dimensional (2D) Nanomaterials: Graphene and Beyond**
Prof. Bengt Fadeel, M.D., Ph.D., A.T.S. Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, (S)

14.45 **Biomedical Applications of Carbon Nanotechnology**
Prof. Dr. Kostas Kostarelos, Professor and Chair of Nanomedicine, Faculty ofBiology, Medicine & Health, University of Manchester, Manchester (UK) and Severo Ochoa Distinguished Professor, Catalan Institute of Nanoscience and Nanotechnology (ICN2), Barcelona (ESP).

15.00 **Questions and Debate**

15.15 **Break**

Hall 1
Monday, 16.15 - 17.45
7. The Use of Novel Nanotherapies in Infection, Inflammation and Chronic Pain (18' + 2' Questions)
Chair **Prof. Dr. med. Patrick Hunziker**, CSO of the CLINAM-Foundation; Deputy Head of the Intensive Care Clinic of the University Hospital Basel and Head of the CLINAM-Lab, Basel (CH)

About The recent pandemic has demonstrated, that infectious diseases are still a major threat to human health and society. Apart from viruses, bacterial infection might become even more dangerous because of the increasing problem of antimicrobial resistance. In order to tackle those challenges, not only novel anti-infectives beyond classical antibiotics are needed, but also innovative technologies to deliver those molecules across various biological barriers. Besides the immune system and epithelial tissues, those also include biofilms and the bacterial cell envelope.

16.15 **Combatting Infections by Integrating the Immune System**
Prof. Dr. Jérôme Galon, Director of Research at INSERM (French NIH), Head of the laboratory of Integrative Cancer Immunology, First class Research Director (DR1) at Institut National de la Santé et de la Recherche Médicale (INSERM), Paris (FR)

16.35 **Inflammation and Pain: Novel Nanotherapies**
Prof. Dr. Patrick Couvreur, University Paris-Saclay, Institut Galien, UFR de Pharmacie, Orsay (FR)

16.55 **Overcoming Biological Barriers in Infectious Diseases**
Prof. Dr. Claus-Michael Lehr, Head of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS-HZI)
and Saarland University, Saarbrücken, Germany

17.15 **Cellular Nanoparticles for Antibacterial Therapy and Vaccination**
Prof. Dr. Liangfang Zhang, Departtment of Nanoengineering, Director, Chemical Engineering Program, University of California San Diego (USA)

17.35 **Questions and Debate**

Foyer of Center
Monday, 15.45 - 17.45
8. CLINAM Posters - Small Speeches (Foyer, Exhibition Hall)
Monday, 15.45 - 17.45
Chair **Dr. Sc. nat. Ruth Schmid,** Vice President Marketing, SINTEF Industry, Biotechnology and Nanomedicine, Polymer Particles and Surface Chemistry, Trondheim (NO)

About Poster submitters have in this session the chance to explain their work in short speeches of 4 - 5 minutes. They highlight in addition research activities in nanotechnology, targeted Delivery and precision medicine at their premises. List of speaker will be presented in September.

Separate Hall
Monday 15.45 - 17.45
9. Closed IPRP (International Pharmaceutical Regulators Programme (upon invitation only)

Hall 1
Monday, 17.45 -19.00
10. Late Breaking Trials and Developments (12' Talks and 3' Questions and Debate)
Chair **NN**

About This session is dedicated to the current trends and challenges in the clinical translation of Nanomedicine as well as the potential pathways for translational development and Commercialization. The speakers present late breaking and ongoing trials.

17.45 **Development of Promitil®, a Lipidic Prodrug of Mitomycin c in Pegylated Liposomes: From Bench to Bedside**
Alberto A. Gabizon, M.D., Ph.D., Director, Center of Nano-oncology, Shaare Zedek Medical Ctr. Professor of Oncology, Hebrew University-School of Medicine, Jerusalem (IL)

18.00 **Normalization of Tumor Microenvironment by Liposomal Delivery of "Normalizing" Agents to Tumors Improving Dramatically Therapeutic Efficacy of Checkpoint Inhibitors**
Prof. Dr. Yechezkel Barenholz, Professor Emeritus, Head of Membrane and Liposome Research Lab, Hebrew University Hadassah Medical School, Jerusalem (IL)

+2 talks

18.45 **Questions and Debate**

19.00 **End of Day**

20.00 **Brokerage and Network Dinner with Cultural Intermezzo's and Allocation of the 2023 CLINAM Dwarf Award**

Tuesday, October 10, 2023 - Parallel Sessions in Hall 1 and 2

Hall 1
Tuesday, 8-30 - 10.30
11. Polymeric Micelles: Preclinical Progress and Clinical Translation (12' plus 3' Questions; Talk 20'plus 5' Questions)
Chair **Prof. Dr. Dr. Twan Lammers,** Institute for Experimental Molecular Imaging, RWTH Aachen, Aachen (D) Aachen (D) **and Dr. Cristianne J. F. Rijcken,** PharmD, PhD, Founder and CSO, Cristal Therapeutics, Maastricht (NL)

About Polymeric micelles are extensively explored as carrier materials for delivering drugs to pathological sites. Many different types of polymeric micelles have been designed and evaluated over the years, and about a dozen of them have been evaluated in patients. This session brings together experts in polymeric micelle design, development and clinical translation, and aims to set the stage for discussing future directions and applications of polymeric micelles for targeted drug delivery.

08.30 **Polymeric Micelle Clinical Translation**
Prof. Dr. Kazunori Kataoka, Director General, Innovation Center of NanoMed, Professor Emeritus, University. Tokyo (JP)

08.55 **Polymeric Micelles vs. Polymer Conjugates**
Prof. Dr. María J. Vicent, Head of Polymer Therapeutics Lab. and Coordinator of Advanced Therapies Area at Centro de Investigación príncipe Felipe (ES)

09.10 **All-PHPMA Polymeric Micelles**
Prof. Dr. ir. W.E. (Wim) Hennink, Division of Pharmacology, Utrecht University, Utrecht (NL)

09.25 **High-Capacity Polymeric Micelles**
Prof. Dr. Robert Luxenhofer Professor, Department of Chemistry · Helsinki Institute of Sustainability Science (HELSUS), Helsinki (FIN)

09.40 **Monitoring Polymeric Micelle Tumor Targeting**
Prof. Dr. Dr. Twan Lammers, Institute for Experimental Molecular Imaging, RWTH Aachen, Aachen (DE)

09.55 **Translational Lessons Learnt**
Dr. Cristianne J. F. Rijcken, PharmD, PhD, Founder and CSO, Cristal Therapeutics, Maastricht (NL)

10.10 **Questions and Debate**

Hall 2
Tuesday, 08.30 - 10.30
12. The Surprising Role of Monoacyl Phospholipids (lysolipids) in Drug Delivery, Medicine, and beyond
A session in Collaboration with the Phospholipid Research Center, Heidelberg
Chair **PD Dr. habil. Simon Drescher, Managing Director, Phospholipid Research Center, Heidelberg (DE)**

About Phospholipids are already included in numerous approved drug products, but their potential is far from exhausted: Phospholipids are extremely well tolerated, and their capabilities go far beyond those of conventional emulsifiers or solubilizes. The two vaccines against COVID-19 based on lipid nanoparticles (LNPs) are a striking example in this respect. When we talk about phospholipids, or more precisely diacyl phospholipids, we must always expect to find monoacyl phospholipids (MAPCs) as well. MAPCs, also known as lysolipids, differ from diacyl phospholipids in terms of their physicochemical characteristics, physiological role, and application. Therefore, despite having the negative reputation of being lytic to erythrocytes, this subgroup offers many positive properties. The goal of this workshop is to introduce the audience to the characteristics of lysolipids, starting with their physicochemical properties, their role within cancer, their usefulness in stabilizing pharmaceutically used proteins, and ending with their applicability in various drug delivery systems.

08.30 **Introduction Phospholipid Research Center**
PD Dr. habil. Simon Drescher, Managing Director, Phospholipid Research Center, Heidelberg (D)

08.35 **Phospholipids as Nanomaterials**
PD Dr. Peter van Hoogevest, CEO PHARMANOVATION .and Member of the Scientific Advisory Council of the Phospholipid Research Center, Heidelberg (DE)

08.40 **The Lysolipids Paradox**
Prof. Dr. Heiko Heerklotz, BIOSS and Institute of Pharmaceutical Sciences, University of Freiburg i. Br (DE)

09.00 **Stabilization of Lyso-phosphatidylcholine-levels in Patients with Cancer**
Prof. Dr. Ulrich Massing, Professor of Pharmaceutical Sciences, University of Freiburg i. Br. (DE)

09.20 **Lyso-phosphatidylcholine for the Stabilization of Pharmaceutical Proteins against Adsorption and Aggregation**
Prof. Dr. Wolfgang Frieß. Chair of Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University, München (DE)

09.40 **Elucidating the Use of Lyso-phospholipids in Oral Self-nanoemulsifying Drug Delivery Systems**
Prof. Dr. Anette Müllertz, Professor, Department of Pharmacy, Faculty of Health and Medical Sciences, Technical University Copenhagen

10.00 **Lecithin and Monoacyl Lecithin as Interacting Excipients in Oral bio-enabling Formulations of Poorly Water-soluble Drugs**
Prof. Dr. Martin Kuentz, University of Applied Sciences and Arts Northwestern Switzerland (CH)

10.20 **Last Questions and Debate**

10.30 **Break**

Hall 1
Tuesday, 11.00 -12.30
13. Lipid Nanoparticles; Changing the Future of Medicine
Session in collaboration with the Lipid Research Days, Vancouver, Canada

Chair **Prof. Dr. Theresa Allen,** University of Alberta, and University of British Columbia and Organizer of the Lipid Research Days 2022, Vancouver (CAN)

About Recent advances in nucleic acid and drug delivery technologies are catalyzing rapid changes in the biotechnology and pharmaceutical Industries on a global scale, enabling personalized medicines, new treatments for rare and undefeated disease and the promise of less expensive treatments for diseases in under-developed countries. This session brings together international experts whose work has been seminal to the development and clinical approval of novel nanomedicines to discuss some ways that nanomedicine will contribute to the changing future of medicine.

11.00 **Rational Design of Lipid Nanoparticles for in Vivo Delivery of mRN**
Prof. Dr. Pieter Cullis. Professor of Biochemistry, University of B.C. (UBC) Vancouver, Cofounder of Acuitas Therapeutics, lipid nanoparticle technology, Vancouver

11.15 **Title to come**
Prof. Dr. Gaurav Sahay, Associate Professor in the Department of Pharmaceutical Sciences, College of Pharmacy at Oregon State University, Corvallis, OR (USA)

11.45 **Title to come**
Prof. Dr. Daniel Siegwart, Associate Professor, Chair in Molecular Oncology Research Department Biochemistry. Biomedical Engineering, Harold C. Simmons Comprehensive Cancer Center, Georgetown (USA)

12.00 **Advancing Lipid Nanoparticles for Safe and Efficient Nucleic acid Delivery to Extrahepatic Tissues**
Dr. Dominik Witzigmann, Chief Executive Officer and Co-founder NanoVation Therapeutics, Vancouver, BC, (CAN)

12.15 **Questions and Debate**

12.30 Lunch

Hall 2
Tuesday, 11.00 -12.30
14. Nanoparticle Based Formulations against AMR

Chair **Prof. Dr. Yechezkel Barenholz,** Hebrew University, Hadassah Medical School, Jerusalem (IL)

About Microbial resistance kills people and impedes control of infectious diseases, damages trade and economies. Has Nanomedicine novel approaches for a new type of drugs for the treatment of infections caused by resistant bacteria? And are besides this other pathways to go against AMR?

11.00 Anatomical and Cellular Barriers for Targeting Pathogens in Rodent and Human Tissues
Prof. Dr. Dirk Bumannm, Center for Molecular Life Sciences, Biozentrum, Basel (CH)

11.20 **Antimicrobial Resistance Research and Development Funding across the Entire Value Chain**
Dr. Ralf Sudbrak, Senior Scientific Programme Officer Global AMR R&D Hub, Berlin (DE)

11.30 **Bacterial Nanomotions Combined with Supervised Machine Learning, Accurately Classify Antibiotic Susceptibility**
Dr. Alexander Sturm, CSO, Resistell AG, Muttenz (CH)

11.40 **Novel Nanodrugs Overcoming AMR**
Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL)

11.50 **Title to come**
Dr. Marc Gitzinger, Founder, Board Member & CEO, BioVersys, Basel (CH)

12.00 **Inorganic Antimicrobials - Nanozymes Combat Bacteria Hiding within Macrophages**
Prof. Dr. Inge Herrmann, Department of Mechanical and Processing Engineering, Nanoparticle Systems Engineering Lab, ETH Zurich (CH)

12.10 **Questions and Debate** with all Speakers

12.30 **Lunch**

Hall 1
Tuesday, 13-30 - 15.20
15. Pharmaceutical Product Design, Development and Manufacturing Insights (APV)
A Session in Collaboration with the International Association for Pharmaceutical Technology (APV), Mainz, Germany

Chair **Dr. Bend Riebesehl,** Executive Director TPPM, Project Head TRD & PHAD Innovation Committee Novartis Leading Scientist, Novartis Campus, Basel (CH)

About We are witnessing now more diverse therapeutic modalities enriching the pharmaceutical product landscape diagnosing or treating unmet medical needs. This session shall feature insights into nanomedicine product design as it addresses unmet drug delivery and patient needs. Also insights into process design insights for GMP manufacturing will inspire peers.

13.30 **LNP-production for mRNA-vaccines, Therapeutics and for Gene-editing – Proof of Concept for a Versatile Process.**
Dr. Andreas Wagner, PPA. Head Liposome Technology, Polymun Scientific Immunbiologische Forschung GmbH, Klosterneuburg (AT)

13.45 **Investigations into mRNA LNP shelf Life Stability**
Dr. Michael Keller, Senior Principal Scientist, Pre-Clinical CMC Pharma Research and Early Development Roche Innovation Center Basel, Basel (CH)

14.00 **Harnessing the Power of Radioactive Isotopes to Treat Patients**
Dr. Lorenza Fugazza, Head TRD Radio Libando Therapy, Novartis, Basel (CH)

+ 3 Talks

15.00 **Questions and Debate**

15.20 **Break**

Session under Construction

Hall 2

Tuesday, 13.30 -15.20

16. Chemistry in or Inspired from Living Systems: From Novel Chemical Tools to Improved Nanomedicine

A Session in Collaboration with the German Research Foundation (DFG) established "Collaborative Research Center on Nanodimensional Polymer Therapeutics for Tumor Therapy" organized by the CRC/SFB, Johannes Gutenberg University, Mainz (DE)

Chair **Prof. Dr. Matthias Barz**, Professor for Bio-pharmacy, Leiden Academic Center for Drug Research (LACDR), Leiden University, (NL) and **Prof. Dr. Lutz Nuhn,** Chair of Macromolecular Chemistry, Institute of Functional Materials and Biofabrication, Faculty of Chemistry and Pharmacy, Julius-Maximilians-University Würzburg, Würzburg (DE)

About The control of chemical reactivity, self-assembly and response mechanisms in small or macromolecules plays an important role in life, but is also entering the spotlight for establishing the next generation nanoparticle-based therapies. In this session we aim to present some latest developments in the areas of bioorthogonal chemistry and life-like nanosystems in Nanomedicine.

13.30 **Pretargeted Imaging and Click to Release ApproachesNext-Level Chemical Tools for Bioorthogonal Click-to-Release**
Prof. Dr. Hannes Mikula, Professor of Chemical Biology Molecular Chemistry and Chemical Biology, TU Vienna, Vienna (AT)

13.40 **In Vivo Click Chemistry as Novel Tool in Immunology**
Sander van Astern, Professor Molecular Immunology, Leiden University (NL)

13.50 **Nanomaterials Communicating with Cells**
Prof. Dr. Tanja Weil, Scientific Member and Director at the Max Planck Institute for Polymer Research, Ulm (DE)

14.05 **Synthetic Biomolecular Condensates**
Prof. Dr. Lu Su, Assistant Professor Science, Leiden Academic Centre for Drug Research LACDR/Drug Delivery Technology, Leiden (NL)

14.15 **Synthetic Transcription Factors**
Prof- Dr. Sebastian Pomplun, Assistant Professor - Drug Discovery Leiden University and Max-Planck Institute for Psychiatry The Hague (NL)

14.25 **Enabling CRISP-Cas9 through Chemical Evolution**
Prof. Dr. Ulrich Lächelt, Group Leader Pharmaceutical Biotechnology. Assistant Professor. Pharmaceutical Biotechnology Center for System-based Drug Research Department of Pharmacy, Munich (DE)

+ 2 Talks

14.55 Q**uestions and Debate**

15.20 **Break**

Hall 1
Tuesday, 15.50 - 17.00
17. Immune-mediated and Related Disorders: Rare and Neglected Diseases, Immunotherapy, Novel Immune Technologies

Chair **Dr. Marina A. Dobrovolskaia Ph.D., MBA, PMP, D**irector of Operations Head of Immunology Section, Nanotechnology Characterization Laboratory, Frederick (USA)

About

16.45 **Questions and Debate**

Session under Construction

Hall 2
Tuesday, 15.50 - 17.00
18. COVID and Beyond

Chair **Dr. Heinrich Haas**, Vice President Formulation & Drug Delivery, BioNTech SE, Mainz (DE) and **Prof. Dr. Moein Moghimi,** Professor of Pharmaceutics and Nanomedicine, School of Pharmacy, Newcastle University, Institute of Cellular Medicine, School of Medicine, Newcastle University (U.K.) and Adjoint Professor, University of Colorado Medical Center, Boulder, CO (USA)

About

16.45 **Questions and Debate**

Session under Construction

17.00 **Short break to gather together in Hall 1 for Plenary Sessions**

Hall 1
Tuesday 17.10 - 18.25
19. Advancing the Development of Novel Bioconjugate-based Therapies: Translating Ideal Wishes Into Daily Practices

Chair **NN**
Industrial Speakers to be announced

Session under Construction

Hall 1
18.30 - 19.15
20. Plenary Lecture

18.30 **Title and speaker to come**

19.00 **Questions and Debate**

19.15 **End of Day**

20.15 **Speakers Dinner at Merian Spitz**

Wednesday, October 11, 2023 - Parallel Sessions in Hall 1 and 2

Hall 1

Wednesday, 08.15 - 10.15

21. Nanocapsules and Nanoparticles Modulating the Immune System: Immunization for Tumors and Dampening Autoimmunity and Allergy

A Session in Collaboration with the German Research Foundation (DFG) established "Collaborative Research Center on Nanodimensional Polymer Therapeutics for Tumor Therapy" organized by the CRC/SFB, Johannes Gutenberg University, Mainz (DE)

Chair **Prof. Dr. med. Volker Mailänder,** Center for Translational Nanomedicine, University Medicine of the Johannes Gutenberg University Mainz (D) **and med. Stephan Grabbe,** Director of the Department of Dermatology, Medical Center and Polyclinic, Speaker of the Research Center for Immunotherapy, Mainz (D)

About Nanotechnology has evolved from liposomes to lipid nanoparticles to an even wider variety of carrier systems. With the success of immunizations against viruses like SARS-CoV2 it became clear that Nanocapsules and nanoparticles are ideal delivery systems for influencing the immune system and delivering immunologically active agents in a hitherto unprecedented way. Beyond developing vaccines for viruses, we will focus in this session on the harder-to-achieve goal of cancer immune treatment by nanocarriers as well as suppressing unwanted immune reactions like in autoimmune diseases or allergies.

08.15 **Targeting Nanocarriers in Vivo and Maximizing Tumor Therapy Effects with Antigen/Adjuvant Combinations in Protein Nanocapsules**
Dr. rer. nat. Michael Fichter, Department of Dermatology, University Medical Center of the Johannes Gutenberg-University Mainz (DE). Max Planck Institute for Polymer Research, Mainz (DE)

08.30 **Cancer Immunotherapy gone # viral: plant Viruses against Cancer**
Prof. Dr. Nicole F. Steinmetz, Department of Nanoengineering, Center for NanoImmuno-Engineering, UC San Diego, USA

08.45 **Employing mRNA against Cancer**
Dr. Mustafa Diken, University Medical Center Mainz, TRON and BioNTec, Mainz, (DE)

09.00 **Ionizable Lipid Nanoparticles in Action & beyond Delivery**
Prof. Dr. Khuloud T. Al-Jamal FRSC, FRPharmS+, FHEA Head of Medicines Development**,** Institute of Pharmaceutical Sciene, King's College London (UK)

09.15 **Lyotropic Nonlamellar Liquid Crystalline Nanoparticles for Immunomodulation**
Prof. Dr. Moein Moghimi, Professor of Pharmaceutics and Nanomedicine, School of Pharmacy, Newcastle University, Institute of Cellular Medicine, School of Medicine, Newcastle University (U.K.) and Adjoint Professor, University of Colorado Medical Center, Boulder, CO (USA)

09.30 **Title to come**
NN

09.45 **Questions and Debate**

10.15 **Break**

Hall 2

Wednesday, 08.15 - 10.15

22. Biosensors, Diagnostics, Imaging-guided Nanomedicine and Targeted Drug Delivery

Chair **Prof. Dr. med. Christoph Alexiou,** Department of Otorhinolaryngology, Head and Neck Surgery, Head Section of Experimental Oncology and Nanomedicine (SEON), Else Kröner-Fresenius-Foundation Professorship, University Hospital Erlangen (D)

About Improved diagnostics, imaging and targeted drug delivery are important core elements of nanomedicine with the aim of providing patients with fast and individual care. In this session different aspects of diagnosis, imaging and targeted therapy will be elucidated with focus on the latest achievements and developments in the field

08.15 **Intrathecal exosomes Brain Imaging for CSF-lymphatic Efflux and Neuroimmue Interface.**
Prof. Dr. med. Dong Soo Lee, PhD, Professor, Seoul National University/POSTECH, Seoul/Pohang (ROK)

08.30 **Tumor Microenvironment Targeting Nanorobots in Cancer**
Prof. Dr. Guangjun Nie, Ph.D, National Center for Nanoscience and Technology, Beijing (CN)

08.45 **Nanomechanics in Diagnosis**
Prof. em. Dr. Christioph Gerber, Department of Physics, University of Basel, Basel (CH)

09.00 **New potential of SPIONs for Diagnostic Purposes**
Prof. Dr. med. Christoph Alexiou, Department of Otorhinolaryngology, Head and Neck Surgery, Head Section of Experimental Oncology and Nanomedicine (SEON), Else Kröner-Fresenius-Foundation Professorship, University Hospital Erlangen (D)

09.15 **Precision Medicine - From Nano-targeting to Theranostics**
Prof. Dr. Paolo Decuzzi, Ph.D. Senior Researcher and Professor, Director, Laboratory of Nanotechnology for Precision Medicine, Italian Institute of Technology, Genova (IT)

10. 00 **Questions and Debate**

Hall 1

Wednesday, 10.45 - 12.15

23. Nanoscale Approaches to Biology

Chair **Prof. Dr. Bert Müller,** Director Biomaterials Science Center Thomas Straumann-Chair for Materials Science in Medicine, University of Basel, Department of Biomedical Engineering, Allschwil (CH)

About Synthetic biology is the engineering and redesign of biological systems. Still today there is limited understanding of the huge potential that synthetic biology offers in Nanomedicine. Biological membranes consist of a continuous double layer of lipid molecules in which membrane proteins are embedded.

10.45 **Biomedical Applications of Synthetic Biology**
Prof. Dr. Lior Nissim, Assistant Professor, Head of the Biomedical Synthetic Biology Group, Hadassah Medical School, The Hebrew University of Jerusalem (IL)

11.00 **CRIPR/Cas9 in the Era of Nanomedicine and Synthetic Biology**
Speaker to be announced

11.15 **Bernoulli principle: Forces Acting on Lipid Bilayers in the Cardiovascular System**
NN

+ 2 Talks

12.00 **Questions and Debate**

Session under construction

12.15 **Lunch**

Hall 2
Wednesday, 10.45 - 12.15
24. Applied Mechanobiology in Nanomedicine
Chair **Prof. Dr. Dr. h.c. Viola Vogel,** Head of the Laboratory of Applied Mechanobiology, Department for Health Sciences and Technology (HEST), ETH, Zürich (CH)

+ 4 talks

12.00 **Questions and Debate**

Session under Construction

12.15 **Lunch**

Hall 1
Wednesday, 13-15 - 15.15
25. Entrepreneurship in Nanomedicine: Novel Concepts, Tools Drug Developments and Therapies
Chair NN

About Academic nanomedicine scientists typically develop highly innovative medicines, often with little regard for translatability. At the same time, academic tech transfer is not properly aligned with the investor and biotech world. To ensure real-life benefits for future patients, new initiatives must be geared at implementing forward-thinking tools aimed at bridging the academia-investor-biotech gap.

13.15 **Treating Disease by Focusing on Innate Immunity**
Prof. Dr. Willem Mulder, Radboud University Medical Center & Eindhoven University of Technology (NL)

13.30 **Title to come**
Prof. Dr. Jörg Huwyler, Professor of Pharmaceutical Technology, University of Basel, Basel (CH)

13.45 **Breaking Barriers with Nanomedicines: Phase 2a Applications in Oncology and Neurology from a Science-Entrepreneur Perspective**
Dr. Stefan Halbherr, PhD, CSO, Research and Development, InnoMedica Holding AG, Bern (CH)

14.00 **Challenges in Clinical Development of Nanomedicines**
Dr. Mark B. van Eldijk, Business Unit Director Nanomedicines, Ardena Oss BV, Oss (NL)

14.15 **The NanoAnalyzer: Combining Flow Cytometry & Particle Analysis to Speed up Nanomedicine development**
Dr. Rob Tempest, Scientific Applications Manager, NanoFCM Co., Ltd., Nottingham (UK)

+ 1 talk

14.45 **Questions and Debate**

15.15 **Break**

Hall 2
Wednesday, 13.15 - 14.15
26. Toxicity- and Safety in Nanomedicine
Chair **NN**

13.15 **3D Printing of Medical Devices: Issues of Patient Safety**
Dr. Ilise Feitshans JD and ScM and DIR, Director, ESI SAFERNANO European Scientific Institute, Archamps (FR); LLM Candidate Georgetown University Law Center Washington DC (USA)

13.30 **How to improve the Toxicology Management in Nanomedicine**
Robert E. Geertsma, M.Sc., Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven (NL) invited

13.45 **Dispelling the Myth - looking at Benefit/ Risk**
Prof. Dr. med. Marisa Papaluca Amati, Regulatory Science and Innovation Visiting Professor, Imperial College London, Department of Primary Care & Public Health School of Public Health Faculty of Medicine, London (UK)

14.00 **Questions and Debate**

Hall 2
Wednesday, 14.15 -15.15
27. Extracellular Vesicles in Nanomedicine – Exosomes
Prof. Dr. med. Raymond Schiffelers, Professor of Nanomedicine;
Division LAB CDL Research; UMC Utrecht; chairman of the ETP Nanomedicine Executive Board, Utrecht (NL)

14.15 **Extracellular Vesicles: Mechanism of Formation, Characterization and Possible Clinical Use**
Prof. Dr. Kirsten Sandvig, Professor, Institute for Cancer Research, the Norwegian Radium Hospital, Oslo University Hospital Montebello, Oslo (N)

+ 4 talks

15.15 **Break**

Hall 1
Wednesday, 15.45 - 17.00
28. Science and Fake Publications - The Current State of Academic Publications
Chair **Prof. Dr. Lajos Balogh**, Editor-in-Chief, "Precision Nanomedicine" Journal, North Andover, MA (USA)

About What makes a publication good and what makes a scientific journal good?

Session under Construction

Hall 2
Wednesday, 15.45 - 17.00
29. Pharmacokineticis in Nanomedicine and Nanocarriers

15.45 **Biodistribution, Pharmacokinetics and Excretion Studies of Intravenously Injected Nanoparticles and Extracelular Vesicles**
Dr. Tore Skotland, Centre for Cancer Biomedicine, Institute for Cancer Research, University of Oslo, (N)

+ 4 talks

Session under Construction

17.00 **Short break to gather together in Hall 1 for Plenary Sessions**

Wednesday, 17-15 - 18.45

17.15 **30. The Regulatory Authorities' Voice 2023**

Chair **to be announced**
Regulatory Authorities Members from all continents

18.45 **Closing Comments by the Organizers**

19.00 **End of Summit 2023**

20 00 **Light Farewell Dinner**

Call for Papers

Topics for Abstracts

Clinical Topics

Nanomedicine and targeted delivery and precision medicine for cardiovascular disease, rheumatic disease, oncology, gastro-intestinal/hepatic disease, bacterial infection, viral infection, parasitic infection, implantology, inflammation, hematology, diabetes, neurology, neurosurgery, orphan diseases, eye and ear disease, tuberculosis, HIV, Ebola, tissue repair, orthopedics, etc.

Technology Topics

Nanosystems, nanoparticles, nano-analytics, and diagnostics, toxicology, nano-imaging, targeted drug delivery, using nanoparticles, GMP and quality assurance, propositions for solving a medical problem in a novel way by the use of nanotechnology, novel concepts and ideas if they can be supported by thorough reasoning and could lead to novel research and solutions. Materials for use in nanotechnology and targeted medicine, concepts, diagnosis and therapy in the field of personalized medicine: clinical diagnosis and management on the individual patient's clinical signs and symptoms, medical and family history, and data from laboratory and imaging evaluation to diagnose and treat illnesses, genetic testing that leads to more personalized treatments. In addition, relevant novel tools for translational research and diagnostics are also of high interest, etc.

Implications Topics and Politics

Implications of nanomedicine for society, developing countries, environment, risks and benefits, public health finance, health economics, and other subjects, government strategy and political strategy building and policy processes in nanomedicine. Strategic approaches towards establishing a unified funding area for nanotechnologies for medical research. Policy processes to foster leadership in nanomedicine, regulatory authority topics, and financial and marketing matters.

Industry Topics

Industry projects and solutions in nanomedicine and targeted medicine, tools related to Nanomedicine, and targeted medicine. Industry models for the future large-scale production, Good manufacturing practice, etc.

Regulatory and Societal Affairs, Networking and Financing Topics

Regulatory issues in nanomedicine, AI and digitalization, strategy and policy, The patient's perspective, Ethical issues in nanomedicine, Cutting-Edge EU-project presentations, networking for international consortium formation, Venture funding, Fund investment, and Business-angel-Investment.

Exhibitors Topics

Integrated interventions of exhibitors that are of high scientific or technical relevance and do not solely have the purpose of promoting the trademark. **Deadline for Submissions of Abstracts**

The Call for oral and poster presentations is open from November 7, 2022 until
July 20, 2023

Submission Procedure (Sending Paper Abstract / Poster Abstract)

Abstract - How to send:

Send us your poster-abstract or oral presentation-abstract (Microsoft Word, RTF, or Open document file format, font size 11, single spacing, NO PDF). The submission must not be no longer than 3 pages, including metadata and figures (one figure is obligatory). All illustrations, figures, and tables must be placed within the text at the appropriate place. Index your file as follows: Last Name.First name.abstract23.docx (or RTF etc.)

Biography

Please add in your mail as a separate document with your NARRATIVE CV, max one page. (This is a cv as story and not tabular (e.g. I was born…, received…, went to. .) No more than 5 titles of recent publications can be included. Index your file as follows: Last name. First name.CV23.docx (or RTF etc.)

Portrait Photo

Send us a head picture in gif or jpg, minimum 300 dpi. DO NOT COPY-PASTE THE PICTURE to Word or Email. Index your file as follows: Last name.First.Name.Picture23 (jpg (or gif)

Sending your papers: All correspondence, (applications for talk or poster with abstracts) and questions or comments relating the Submission 2023 have to be sent to submiss23@clinam.org

Decision for Acceptance

The decision to accept or decline your work will be given as soon as possible but at the latest within 7 weeks after submission. You will receive a Decision-E-Mail, stating the acceptance or declination from one of the organizers for either an oral presentation or a Poster presentation. Decisions of the Committee cannot be discussed.

Presentation Times, Size of Posters, Installation of Posters

Posters are to be presented in the size of 1.40 meters high and 1.00 meter wide. Advice for installation will be communicated in time.

Small Speeches for Poster Presenters

Poster presenters can apply to give a short oral presentation in a special session of Small Speeches, 4 minutes in length. They must comprise three slides, • Slide 1: general introduction to the topic • Slide 2: some of the highlights of submitter's work and institution's work • Slide 3: the proof as to how the work fits into the area of Nanomedicine or Precision Medicine, including a glimpse into the future. Application for a small speech is only possible after your poster has been accepted. The Head of Session, Dr. Ruth Schmid, will select speeches based on a committee's recommendation. The best 30 presentations will be allowed for speaking. To apply, write a mail indicating the institution, the person to be addressed and full address & phone number. In the heather line, write "APPLICATION FOR SMALL SPEECH 2023."
Address: smallspeeches23@clinam.org

Fellowship

The Fellowship reduces the prize for attendance to 100.00 and includes the full Summit-Ticket. Those receiving a fellowship must mandatorily submit an abstract of the proposed poster or talk together with the application . Attach abstract with your submission letter to CLINAM and justify the request for the fellowship. Add a reference letter by a superior of your organization. Fellowship Applicants receive a decision by email within 8 weeks after sending their submission. 40 fellowships are available. For sending use: Fellow23@clinam.org

The Organizers of CLINAM

Organisation Office	**Registration Office**
European Foundation for Clinical Nanomedicine Beat Löffler and Joshua Kanters Alemannengasse 12 CH-4058 Basel Switzerland clinam@clinam.org Phone +41 61 695 93 95 Mobile +41-78 654 37 07	Viva Management GmbH Abhinay Agarwal Kramgasse 16 CH-3011 Bern, Switzerland. clinam@vivamanagement.ch Phone +41 31 311 74 34

Registration for the Summit

ONLINE REGISTRATION ONLY. Payment by credit card (MasterCard or VISA)

The registration includes the entire programme, proceedings, aperitif, lunch and coffee breaks on Monday, Tuesday and Wednesday of the summit. Sunday afternoon there will be an Expert-Intervention for young scientific members, at 7.00 pm rich welcome aperitif for all members arriving on Sunday.

Currency is EURO	**3 Days Early Bird until 5.8. 2023**	**3 Days Regular as from 6.8. 2023**	**1 Day**
Virtual Participation	360.00 €		
Academy, NPO	680.00 €	750.00 €	390.00 €
Invited Speakers	250.00 € (optional: ☐ I can contribute ☐ Not at this moment) Option will be in the registration folder		
Submitting Speakers	450.00 €		
Poster Presenters	400.00 €		
Poster Presenters Student	360.00 €		
Industry & Government	1'000.00 €	1'400.00 €	800.00 €
Exhibitors	Exhibition space 3'500.00 € incl. one exhibitors registration		
Students	360.00 €		
Fellowships	A restricted number of Fellowships will be given for 100.00 € Participation in the events is not included		
Networking Dinner open to all participants MO 9.10.	70.00 € This evening is a concert dinner event for networking and awarding the CLINAM Dwarf Award 2023		
Invited Speakers & Special Guests Dinner TUE 10.10.	Upon Invitation		
Light Farewell Dinner WED 11.10	60.00 €		

Portraits of the Joining Organizers of Excellence Contributing with a Session

The Phospholipid Research Center Heidelberg, Germany

Phospholipid Research Center (PRC) was founded in 2006 by renowned international scientists, each of them conducting research in phospholipids, and with the support of Lipoid GmbH and Phospholipid GmbH. Both companies have continued providing financial donations to the PRC to this day. In the interest of an open and fruitful dialogue between all scientists and developers involved in phospholipids throughout the world, the PRC was conceived as an independent non-profit organization from the very beginning. Since 2006, the PRC has been funding research on phospholipid excipients for pharmaceutical and cosmetic use. The aim is to expand the knowledge on pharmaceutical and technical applications of phospholipid excipients, their ability to improve, for example, the bioavailability and tolerability of active pharmaceutical ingredients in oral, topical, pulmonary, and parenteral dosage forms, and their use as

active ingredients. Individual researchers and research groups from all around the world are therefore encouraged to submit a research proposal to apply for funding of research for non-commercial purposes. Especially PhD and Postdoc projects at academic institutes are in focus. More information can be found on www.phospholipid-research-center.com PRC—Connecting the World of Phospholipids.

Liposome Research Days, Vancouver, Canada

Liposomes Research Days (LRD) was founded in 1990 by Hans Schrier at a meeting in Gainsville Florida. International LRD meetings have been held approximately every two years for the last 32 years, rotating between Europe, North America and Asia. LRD meetings are organized at each location by a volunteer group of internationally recognized scientists specializing in liposome and lipid nanoparticle basic research and translation, and in lipid membrane biophysics. It is a loosely organized non-profit organization that honors a senior member of the organization each meeting with the awarding of the prestigious A.D. Bangham FRS Life Achievement Award. Prizes for are also awarded each meeting to junior researchers judged to have the best quality posters.The last LRD meeting was held in Vancouver, Canada in 2022 with over 300 international attendees from academia and industry in attendance. For 2023, the LRD shall have a session during the CLINAM Summit in Basel. https://www.nanomedicines.ca/lrd-2022/#about

International Association for Pharmaceutical Technology (APV), Driver of Pharmaceutical Progress

APV is the independent, international and interdisciplinary scientific organization focusing on pharmaceutical technology and industrial pharmacy. Our goal is to deepen the understanding in scientific research and practical knowledge in the areas of development, manufacturing, analysis, quality assurance, distribution and use of pharmaceuticals as well as medical devices and to educating all relevant professionals in order to provide effective and save health products for patient care now and in future. https://www.apv-mainz.de/pharma-verfahrenstechnik/

Venue for the Summit

The Architect Frank Owen Gehry, is a Canadian-born American architect and designer with world-renowned buildings. His style is considered deconstructivist, a movement in postmodern architecture where elements of the design appear to be fragmented. His architecture is typically characterized by flowing lines, and surfaces that vary from titanium cladding to metal Blobitectural modular parts.



Copyright: Novartis

Exhibitors at the 14th European and Global Summit for Clinical Nanomedicine 2023

…and further exhibitors to come

CLINAM Exhibition 2023 Profit

Exhibitors at the CLINAM Summit 2023 profit from meeting their potential clients in one spot since CLINAM is presently the world´s largest summit on Clinical Nanomedicine with thus year 300-400 participants in need of tools, systems platforms findings, research results and other devices.

SMEs and start-up companies have the chance to display their skills and to meet a group including all stakeholders in the field of clinical nanomedicine, targeted delivery and precision medicine and related fields. This is a Foyer exhibition All breaks and catering for lunches are held in midst of the CLINAM marketplace.

Registration for the Exhibition

I herewith register a space of 6m2 in the foyer of the halls at Novartis from October 8 -11, 2023 at the rate of 3'500.00 € incl. one exhibitor's registration.

Company name
Contact person
Street
ZIP / Place Country
Phone landline
Phone Mobile
E-Mail

Since there is only space and no booth construction we offer separate services as follows:

0	Company name A3 on pillar	100 €
0	1 table, 2 chairs	130 €
0	1 pin board for poster	40 €
0	Power connection	30 €
0	Further Exhibitors Registrations (add how many) (rate equivalent to early bird tariff)	1000 €

Please confirm with signature on the folder your order and send it to a scan to loeffler@clinam.org with the reference "exhibition"

CLINAM IN THE MEDIA

See the journal at https://precisionnanomedicine.com/

PRNANO - The official journal of CLINAM and ISNM

A peer-reviewed, international nonprofit platinum Open Access online journal, Indexed in SCOPUS and DOAJ

INVITATION TO PUBLISH IN PRECISION NANOMEDICINE on behalf of CLINAM and Andover House

This journal does not charge submission or article procession fees, and authors retain ownership of their work. All content is freely available to the user or his/her institution. Users (including authors) are allowed to submit, read, download, copy, print, share, search, or link to the full texts of the articles or use them for any other lawful purpose without asking prior permission from the publisher or the author.

The Mission

The journal promotes all practical, rational, and progressive aspects of nanomedicine including theory and practice in basic science, translational, preclinical, and clinical research. PRNANO accepts original manuscripts**,** as well as replication studies and discussions of negative results if they move the field forward.

The journal's aim and scope are to distribute good quality, reproducible, and reliable articles with a quick turnaround time. PRNANO supports publications of CLINAM members, members of other national nanomedicine societies, and nanomedicine researchers.

Previously presented works

We support authors who wish to share their work early through the deposition of manuscripts with preprint servers such as bioRxiv or arXiv, have previously been presented at conferences, published as a thesis, or have previously appeared in other "non-journal" venues (e.g., blogs or posters).

Supporting peer-review

PRNANO provides a cutting-edge and encouraging peer-review process from its Editorial Board members, forty-five of which belong to the World's top 2% of scientists and 25 to 1% by citations.

Articles are published continuously

They are organized into quarterly issues and annual volumes. All articles receive a unique identifier (DOI:10.33218/001c.#####) and are archived both in Portico and Crossref, for preservation. We are members of COPE (https://publicationethics.org/members/precision-nanomedicine).

Publisher:

Precision Nanomedicine is published by Andover House, Inc, (www.andoverhouse.org), a not-for-profit online publisher founded by scientists and professionals in Massachusetts, USA.

Sponsors of the CLINAM Summit and the CLINAM Foundation



--and further Sponsors